Home > Oncology > ASCO 2019 > Genitourinary Cancer - Prostate Cancer > Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer

Presented By
Dr Kim N. Chi, BC Cancer Agency, Canada
Conference
ASCO 2019
Trial
Phase 3, TITAN
Medical writer: Tim Donald, ELS The addition of apalutamide to androgen-deprivation therapy (ADT) significantly improved radiographic progression-free survival (rPFS) and overall survival (OS) in patients with metastatic castration-sensitive prostate cancer (mCSPC) in the TITAN trial, according to a presentation on May 31 during a Genitourinary (Prostate) Cancer Oral Abstract Session (Abstract 5006). The safety profile of the regimen was tolerable in the trial, according to presenter Kim N. Chi, MD, FRCPC, of BC Cancer Agency, Canada. “These results support the addition of apalutamide to ADT for a broad range of patients with mCSPC, such as those in the TITAN study, which included patients with high- and low-volume disease, with prior docetaxel treatment, those who had metastatic disease at diagnosis or relapsed metastatic disease, and those who had received prior treatment for localized disease,” Dr. Chi said. The results he presented were based on ...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on